STOCK WATCH

IXICO, a company that provides analysis for brain scan data, received a boost to its share price yesterday after landing a contract worth more than £550,000.

The group said that under the deal it will support a phase two clinical trial for a potential treatment for Alzheimer’s disease.

It added that the agreement was with a ‘top-five’ clinical research organisation.

The trial will be conducted on patients with mild to moderate Alzheimer’s across 41 sites in the US and Europe.

Ixico’s shares jumped by 8.1pc, or 6p, to 80p following the announcement.